PharmaCyte raises CEO and CFO salaries; Nasdaq confirms listing compliance

PharmaCyte Biotech, Inc.

CEO Kenneth Waggoner salary increased from $375K to $520K, retroactive to Jan 1, 2022.
CFO Carlos Trujillo salary increased from $275K to $380K, retroactive to Jan 1, 2022.
Nasdaq Staff determined company meets independent director requirement after appointing Dr. Matthias Löhr.

item 5.02 item 8.01

PharmaCyte Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-22-002580

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.